Royal Bank Of Canada Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $128.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target decreased by Royal Bank Of Canada from $130.00 to $128.00 in a research report sent to investors on Thursday, Marketbeat reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Other research analysts have also recently issued research reports about the stock. Citizens Jmp dropped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday. Raymond James Financial restated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $114.92.

Mirum Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ MIRM opened at $92.29 on Thursday. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $109.28. The firm’s 50-day simple moving average is $93.40 and its 200 day simple moving average is $79.18. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The company has a market cap of $5.57 billion, a price-to-earnings ratio of -192.27 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.98% and a negative net margin of 4.48%.The company had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. During the same period in the prior year, the firm posted $1.00 earnings per share. The company’s revenue was up 49.8% on a year-over-year basis. On average, research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97. Following the completion of the transaction, the insider owned 11,305 shares in the company, valued at approximately $1,020,502.35. The trade was a 37.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Peter Radovich sold 3,143 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17. Following the completion of the sale, the chief operating officer owned 23,286 shares in the company, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,136 shares of company stock worth $4,352,029 over the last ninety days. 14.36% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Mackenzie Financial Corp grew its stake in Mirum Pharmaceuticals by 425.2% in the fourth quarter. Mackenzie Financial Corp now owns 19,889 shares of the company’s stock valued at $1,565,000 after acquiring an additional 16,102 shares during the period. XTX Topco Ltd bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $3,179,000. Zacks Investment Management bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $2,401,000. Vestal Point Capital LP acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $5,213,000. Finally, Virtus Investment Advisers LLC increased its stake in Mirum Pharmaceuticals by 16.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 10,513 shares of the company’s stock worth $830,000 after purchasing an additional 1,447 shares in the last quarter.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.